Midecamycin: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
No edit summary |
||
Line 1: | Line 1: | ||
<div style="float: right;"> | |||
[[File:Midecamycin.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div> | |||
| | __NOTOC__ | ||
| | |||
| | |||
| | |||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
==Overview== | |||
'''Midecamycin''' is a [[macrolide]] [[antibiotic]]. Synthesized from ''Streptomyces mycarofaciens''. | |||
==Physical Properties== | |||
[[Melting point]] vary depending on the compound type. It may also vary depending on the source consulted. Example: | |||
For the A<sub>1</sub> type: | |||
The Merck Index reports 155-156 [[Celsius]]. | |||
The [[Japanese Pharmacopoeia]] reports 153–158 Celsius. | |||
For the A<sub>3</sub> type: | |||
The Merck Index reports 122-125 Celsius. | |||
==References== | |||
{{reflist|2}} | |||
[[ | {{Macrolides, lincosamides and streptogramins}} | ||
[[Category:Macrolide antibiotics]] | |||
[[Category:Drug]] |
Revision as of 19:59, 7 April 2015
WikiDoc Resources for Midecamycin |
Articles |
---|
Most recent articles on Midecamycin Most cited articles on Midecamycin |
Media |
Powerpoint slides on Midecamycin |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Midecamycin at Clinical Trials.gov Clinical Trials on Midecamycin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Midecamycin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Midecamycin Discussion groups on Midecamycin Patient Handouts on Midecamycin Directions to Hospitals Treating Midecamycin Risk calculators and risk factors for Midecamycin
|
Healthcare Provider Resources |
Causes & Risk Factors for Midecamycin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Midecamycin is a macrolide antibiotic. Synthesized from Streptomyces mycarofaciens.
Physical Properties
Melting point vary depending on the compound type. It may also vary depending on the source consulted. Example:
For the A1 type:
The Merck Index reports 155-156 Celsius. The Japanese Pharmacopoeia reports 153–158 Celsius.
For the A3 type:
The Merck Index reports 122-125 Celsius.
References